- Home
- MLYS vs UFCS Comparison
MLYS vs UFCS Comparison
Compare MLYS & UFCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- UFCS
- Stock Information
- Founded
- MLYS 2019
- UFCS 1946
- Country
- MLYS United States
- UFCS United States
- Employees
- MLYS N/A
- UFCS N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- UFCS Property-Casualty Insurers
- Sector
- MLYS Health Care
- UFCS Finance
- Exchange
- MLYS Nasdaq
- UFCS Nasdaq
- Market Cap
- MLYS 634.6M
- UFCS 642.7M
- IPO Year
- MLYS 2023
- UFCS N/A
- Fundamental
- Price
- MLYS $9.77
- UFCS $26.48
- Analyst Decision
- MLYS Strong Buy
- UFCS Hold
- Analyst Count
- MLYS 2
- UFCS 1
- Target Price
- MLYS $30.00
- UFCS $26.00
- AVG Volume (30 Days)
- MLYS 266.6K
- UFCS 151.3K
- Earning Date
- MLYS 11-11-2024
- UFCS 02-11-2025
- Dividend Yield
- MLYS N/A
- UFCS 2.42%
- EPS Growth
- MLYS N/A
- UFCS N/A
- EPS
- MLYS N/A
- UFCS 1.94
- Revenue
- MLYS N/A
- UFCS $1,207,451,000.00
- Revenue This Year
- MLYS N/A
- UFCS N/A
- Revenue Next Year
- MLYS N/A
- UFCS $11.31
- P/E Ratio
- MLYS N/A
- UFCS $13.59
- Revenue Growth
- MLYS N/A
- UFCS 10.95
- 52 Week Low
- MLYS $8.58
- UFCS $18.04
- 52 Week High
- MLYS $16.91
- UFCS $31.70
- Technical
- Relative Strength Index (RSI)
- MLYS 37.52
- UFCS 39.63
- Support Level
- MLYS $9.18
- UFCS $25.20
- Resistance Level
- MLYS $9.97
- UFCS $27.43
- Average True Range (ATR)
- MLYS 0.85
- UFCS 0.72
- MACD
- MLYS -0.25
- UFCS -0.18
- Stochastic Oscillator
- MLYS 24.53
- UFCS 33.60
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.